PL2148676T3 - Stosowanie sapacytabiny do leczenia choroby proliferacyjnej - Google Patents
Stosowanie sapacytabiny do leczenia choroby proliferacyjnejInfo
- Publication number
- PL2148676T3 PL2148676T3 PL08737080.5T PL08737080T PL2148676T3 PL 2148676 T3 PL2148676 T3 PL 2148676T3 PL 08737080 T PL08737080 T PL 08737080T PL 2148676 T3 PL2148676 T3 PL 2148676T3
- Authority
- PL
- Poland
- Prior art keywords
- sapacitabine
- proliferative disease
- treat proliferative
- treat
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0708021A GB0708021D0 (en) | 2007-04-25 | 2007-04-25 | Use |
GB0723723A GB0723723D0 (en) | 2007-12-04 | 2007-12-04 | Use |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2148676T3 true PL2148676T3 (pl) | 2016-12-30 |
Family
ID=39719125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08737080.5T PL2148676T3 (pl) | 2007-04-25 | 2008-04-24 | Stosowanie sapacytabiny do leczenia choroby proliferacyjnej |
Country Status (6)
Country | Link |
---|---|
US (2) | US8536188B2 (ja) |
EP (1) | EP2148676B1 (ja) |
JP (2) | JP5852309B2 (ja) |
ES (1) | ES2587381T3 (ja) |
PL (1) | PL2148676T3 (ja) |
WO (1) | WO2008132443A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
JP5852309B2 (ja) | 2007-04-25 | 2016-02-03 | サイクラセル リミテッド | 増殖性疾患を治療するためのサパシタビンの使用 |
CA2723944A1 (en) * | 2008-05-15 | 2009-11-19 | Jan Balzarini | Anti-cancer combination therapy |
ES2743691T3 (es) * | 2011-04-14 | 2020-02-20 | Cyclacel Ltd | Régimen de dosis para sapacitabina y decitabina en combinación para tratar la leucemia mieloide aguda |
EP2874631A1 (en) | 2012-05-15 | 2015-05-27 | Cyclacel Limited | Dosage regimen for sapacitabine and seliciclib |
PT2941233T (pt) * | 2013-01-07 | 2020-11-13 | Univ Pennsylvania | Composições e métodos para tratar linfoma cutâneo de células t |
WO2021079129A1 (en) | 2019-10-24 | 2021-04-29 | Cyclacel Limited | Dosing regimen |
CN113727719A (zh) * | 2020-07-17 | 2021-11-30 | 德尔塔菲制药股份有限公司 | 血癌的新型治疗方法及新型治疗剂 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100402029C (zh) * | 2002-03-08 | 2008-07-16 | 诺瓦提斯公司 | 包含埃坡霉素衍生物和烷化剂的组合 |
US20050014716A1 (en) * | 2003-05-21 | 2005-01-20 | Wang Jin Wei | Pancreatic cancer treatment |
CA2591705A1 (en) * | 2004-12-21 | 2006-06-29 | Schering Corporation | Novel farnesyl protein transferase inhibitors as antitumor agents |
AU2006209547C1 (en) * | 2005-01-26 | 2022-04-07 | Taiho Pharmaceutical Co., Ltd. | Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor |
JP2009504774A (ja) * | 2005-08-18 | 2009-02-05 | メルク エンド カムパニー インコーポレーテッド | 癌を治療するためにsaha及びターグレチンの併用方法 |
GB0526419D0 (en) * | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
GB0609530D0 (en) * | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
GB0625283D0 (en) | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
JP5852309B2 (ja) | 2007-04-25 | 2016-02-03 | サイクラセル リミテッド | 増殖性疾患を治療するためのサパシタビンの使用 |
-
2008
- 2008-04-24 JP JP2010504828A patent/JP5852309B2/ja not_active Expired - Fee Related
- 2008-04-24 ES ES08737080.5T patent/ES2587381T3/es active Active
- 2008-04-24 US US12/597,293 patent/US8536188B2/en active Active
- 2008-04-24 EP EP08737080.5A patent/EP2148676B1/en active Active
- 2008-04-24 PL PL08737080.5T patent/PL2148676T3/pl unknown
- 2008-04-24 WO PCT/GB2008/001424 patent/WO2008132443A1/en active Application Filing
-
2013
- 2013-08-15 US US13/967,901 patent/US9675631B2/en active Active
-
2014
- 2014-08-25 JP JP2014170018A patent/JP5892565B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8536188B2 (en) | 2013-09-17 |
EP2148676B1 (en) | 2016-05-25 |
WO2008132443A1 (en) | 2008-11-06 |
US9675631B2 (en) | 2017-06-13 |
JP2010525042A (ja) | 2010-07-22 |
JP5892565B2 (ja) | 2016-03-23 |
US20140142058A1 (en) | 2014-05-22 |
EP2148676A1 (en) | 2010-02-03 |
JP5852309B2 (ja) | 2016-02-03 |
ES2587381T3 (es) | 2016-10-24 |
US20100125084A1 (en) | 2010-05-20 |
JP2015013877A (ja) | 2015-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211889A1 (en) | Therapeutic use of diaminophenothiazines | |
BRPI0914614A2 (pt) | 2-arilaminoquinazolinas para tratar doenças proliferativas | |
HK1154575A1 (zh) | 用於治療增生性疾病的不對稱吡咯並苯並二氮雜卓二聚物 | |
IL230335A (en) | A drug used to treat cartilage disease | |
HK1173654A1 (zh) | 治療化合物及相關的使用方法 | |
ZA201101818B (en) | Modified release emulsions for application to skin or viginal mucosa | |
BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
IL209855A0 (en) | Supression of neuroedocrine diseases | |
GB0908193D0 (en) | Treatment of disease state | |
PL2148676T3 (pl) | Stosowanie sapacytabiny do leczenia choroby proliferacyjnej | |
EP2160100A4 (en) | TREATMENT OF GRAFT REJECTION DISEASE | |
EP2300608A4 (en) | METHODS OF TREATING SOLID TUMORS | |
HK1141708A1 (en) | Agent for treatment of pulmonary disease | |
EP2210621A4 (en) | COMPOSITION FOR THE TREATMENT OF JOINT DISEASES | |
IL211076A0 (en) | Novel methylenedioxy phenolic compounds and their use to treat disease | |
EP2249826A4 (en) | COMPOSITIONS AND METHODS OF USING COMPOUNDS TO EXTEND THE SURVIVAL PERIOD OF CANCER PATIENTS | |
ZA201003867B (en) | Treatment of heart disease using b-blockers | |
GB0723100D0 (en) | Treatment of HFnEF | |
ZA201005783B (en) | Hard to reach fracture applicator strap | |
EP2507266A4 (en) | TREATMENT OF IGE-MEDIATED DISEASES | |
GB0817859D0 (en) | Treatment of proteostatic disease | |
GB0819543D0 (en) | Treatment of proteostatic disease | |
GB0908666D0 (en) | Treatment of proteostatic disease | |
GB0911418D0 (en) | Treatment of degenerative disc disease | |
HU0800656D0 (en) | Effective use of tea-composition |